Results 31 to 40 of about 658,413 (361)
GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. [PDF]
, 2016 Abnormal activation of the epidermal growth factor receptor (EGFR) due to a deletion of exons 2-7 of EGFR (EGFRvIII) is a common alteration in glioblastoma (GBM). While this alteration can drive gliomagenesis, tumors harboring EGFRvIII are heterogeneous.
David James, C +11 more
core +1 more source
Selective Desensitization of Growth Factor Signaling by Cell Adhesion to Fibronectin [PDF]
, 2007 Cell adhesion to the extracellular matrix is required to execute growth factor (GF)-mediated cell behaviors, such as proliferation. A major underlying mechanism is that cell adhesion enhances GF-mediated intracellular signals, such as extracellular ...
Asthagiri, Anand R. +3 more
core +1 more source
Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report [PDF]
, 2013 BACKGROUND: Although a number of studies have reported acquired drug resistance due to administration of epidermal growth factor receptor antibody inhibitors, the underlying causes of this phenomenon remain unclear.
Akio Saiura +8 more
core +1 more source
Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients
Clinics, 2012 OBJECTIVE: Epidermal growth factor receptor is involved in the pathogenesis of non-small cell lung cancer and has recently emerged as an important target for molecular therapeutics.
Carlos E. Bacchi +5 more
doaj +1 more source
Technology in Cancer Research & Treatment, 2020 Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors ...
Yi-Tian Qi MM +2 more
doaj +1 more source
Coexistence of three EGFR mutations in an NSCLC patient: A brief report [PDF]
, 2018 The epidermal growth factor receptor (EGFR) represents a molecular target for tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC) patients with a mutation in the EGFR gene. Mutations of the EGFR gene that occur at a single position in NSCLC
Belardinilli, Francesca +8 more
core +1 more source
Technology in Cancer Research & Treatment, 2020 Background: To investigate the mechanism of microRNA9 in inhibiting proliferation and migration of lung squamous cell carcinoma cells via neuron-restricted silencing factor/epidermal growth factor receptor.
Kangning Wang MD +4 more
doaj +1 more source
Activation of tyrosine kinases by mutation of the gatekeeper threonine. [PDF]
, 2008 Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the gatekeeper threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth ...
Azam, Mohammad +4 more
core +1 more source
Reciprocal control of viral infection and phosphoinositide dynamics
FEBS Letters, EarlyView.Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley +1 more source
Specific Rab GTPase-activating proteins define the Shiga toxin and epidermal growth factor uptake pathways [PDF]
, 2007 Rab family guanosine triphosphatases (GTPases) together with their regulators define specific pathways of membrane traffic within eukaryotic cells. In this study, we have investigated which Rab GTPase-activating proteins (GAPs) can interfere with the ...
Barr, Francis A. +5 more
core +2 more sources